Anatomic Stage II Breast Cancer AJCC v8 research hub

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This study looks at whether some people with early triple-negative breast cancer who had a good response to initial treatment can skip further immunotherapy after surgery. It compares continuing pembrolizumab with just being watched closely to see if both approaches are equally good at preventing cancer from coming back.